GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Cyclically Adjusted PS Ratio

NeoGenomics (NeoGenomics) Cyclically Adjusted PS Ratio : 3.44 (As of Jun. 01, 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Cyclically Adjusted PS Ratio?

As of today (2024-06-01), NeoGenomics's current share price is $13.71. NeoGenomics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.98. NeoGenomics's Cyclically Adjusted PS Ratio for today is 3.44.

The historical rank and industry rank for NeoGenomics's Cyclically Adjusted PS Ratio or its related term are showing as below:

NEO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.93   Med: 6.43   Max: 23.86
Current: 3.44

During the past years, NeoGenomics's highest Cyclically Adjusted PS Ratio was 23.86. The lowest was 1.93. And the median was 6.43.

NEO's Cyclically Adjusted PS Ratio is ranked worse than
64.66% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.35 vs NEO: 3.44

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NeoGenomics's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.239. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.98 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for NeoGenomics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Cyclically Adjusted PS Ratio Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.28 21.43 11.50 2.71 4.22

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 4.40 3.27 4.22 3.95

Competitive Comparison of NeoGenomics's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted PS Ratio falls into.



NeoGenomics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

NeoGenomics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=13.71/3.98
=3.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, NeoGenomics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.239/131.7762*131.7762
=1.239

Current CPI (Mar. 2024) = 131.7762.

NeoGenomics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.385 100.560 0.505
201409 0.426 100.428 0.559
201412 0.401 99.070 0.533
201503 0.382 99.621 0.505
201506 0.403 100.684 0.527
201509 0.415 100.392 0.545
201512 0.448 99.792 0.592
201603 0.785 100.470 1.030
201606 0.815 101.688 1.056
201609 0.778 101.861 1.006
201612 0.614 101.863 0.794
201703 0.730 102.862 0.935
201706 0.784 103.349 1.000
201709 0.743 104.136 0.940
201712 0.767 104.011 0.972
201803 0.788 105.290 0.986
201806 0.751 106.317 0.931
201809 0.760 106.507 0.940
201812 0.793 105.998 0.986
201903 1.009 107.251 1.240
201906 0.994 108.070 1.212
201909 0.970 108.329 1.180
201912 1.007 108.420 1.224
202003 1.015 108.902 1.228
202006 0.806 108.767 0.977
202009 1.052 109.815 1.262
202012 1.013 109.897 1.215
202103 0.994 111.754 1.172
202106 0.928 114.631 1.067
202109 0.990 115.734 1.127
202112 1.026 117.630 1.149
202203 0.948 121.301 1.030
202206 1.008 125.017 1.063
202209 1.035 125.227 1.089
202212 1.112 125.222 1.170
202303 1.098 127.348 1.136
202306 1.172 128.729 1.200
202309 1.209 129.860 1.227
202312 1.235 129.419 1.257
202403 1.239 131.776 1.239

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (NAS:NEO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


NeoGenomics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913

NeoGenomics (NeoGenomics) Headlines

From GuruFocus

NeoGenomics Inc's Stock Performance: A Detailed Analysis

By GuruFocus Research 11-14-2023